28 North Discovery Limited
Registered name: 28 NORTH DISCOVERY LIMITED
Part of CN Bio Innovations Limited group28 North Discovery Limited does not publish its revenue or profit. Its accounts to 31 Dec 2023 show net assets of -£926k.
28 North Discovery Limited did not publish its revenue or profit — small companies aren’t required to file a profit & loss account. Its accounts for the year to 31 Dec 2023 showed net assets of −£926k and 0 employees. The company is classified under “research and experimental development on biotechnology” and is based in Cambridge; we hold 3 years of its filed accounts.
- Status
- Active
- Location
- Cambridge, East of England
- Age
- 9 yrs · since 2016
- Type
- Private Limited Company
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.
Key figures
Revenue not disclosed
28 North Discovery Limited’s accounts for the year to 31 Dec 2023 contain a balance sheet but no profit & loss account, so its revenue and profit are not public. UK small and micro-entity companies are not required to publish a P&L — this is normal and says nothing about how the business is performing.
We never estimate revenue. Below you’ll find the balance-sheet figures that were filed — useful as indirect signals of momentum, but they are not revenue or profit.
- Employees
- 0
- Net assets
- −£926k
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Dec 2021 | 31 Dec 2022 | 31 Dec 2023 |
|---|---|---|---|
| Disclosure | No P&L | No P&L | No P&L |
| Profit & loss | |||
| Revenue (turnover) | — | — | — |
| Profit (best available) | — | — | — |
| Employees (average) | 0 | 0 | 0 |
| Ratios | |||
| Profit margin | — | — | — |
| Balance sheet — indirect signals, not revenue | |||
| Net assets | −£840k | −£882k | −£926k |
| Source | AbridgedAccounts · bulk data Dec 2023 | AbridgedAccounts · bulk data Dec 2023 | AbridgedAccounts · bulk data Sep 2024 |
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- —
- Now −£926k
- Cash at bank
- —
- Now —
- Headcount
- —
- Now 0
- Deferred income
- —
- Now —
- Fixed assets
- —
- Now —
Group structure
Ownership chain
- CN Bio Innovations Limitedultimate parent75–100%
- 28 North Discovery Limitedthis company
Bands show the share of ownership each company holds in the one below it.
From the Persons with Significant Control register (corporate controllers only).
Similar profitable businesses
- Astex Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £404m
- Profit
- £283m
- Staff
- 183
- Amphista Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £33.9m
- Profit
- £19.8m
- Staff
- 56
- Charles River U.K. LimitedKent · Research and experimental development on biotechnology
- Revenue
- £22.2m
- Profit
- £18.8m
- Staff
- 129
- Qiagen Manchester LimitedManchester · Research and experimental development on biotechnology
- Revenue
- £53.7m
- Profit
- £11.8m
- Staff
- 239
- Alchemab Therapeutics LtdLondon · Research and experimental development on biotechnology
- Revenue
- £30m
- Profit
- £8.3m
- Staff
- 55
- Ligand UK Development LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £8.7m
- Profit
- £6m
- Staff
- —
Sources
Latest figures from AbridgedAccounts for the year to 31 Dec 2023, from the Companies House accounts bulk data published Sep 2024. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.